Drugs in Dev. Nephrology
IND Enabling
United Kingdom 
Lead Product(s) : PS-002
Therapeutic Area : Nephrology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Purespring Wins EMA Orphan Drug Status for PS-002 in IgA Nephropathy
Details : PS-002 is a Purespring’s lead cell and gene therapy programme, currently being investigated in patients with IgA nephropathy (IgAN).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 28, 2025
Lead Product(s) : PS-002
Therapeutic Area : Nephrology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PS-002
Therapeutic Area : Nephrology
Study Phase : IND Enabling
Sponsor : Sofinnova Partners
Deal Size : $105.0 million
Deal Type : Series B Financing
Purespring Therapeutics Raises $105M to Transform Kidney Disease Treatment
Details : The proceeds will be used to support Purespring’s pipeline including the initiation of a Phase I/II clinical trial of PS-002 for IgAN, a chronic kidney disease primarily affecting young adults.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 09, 2024
Lead Product(s) : PS-002
Therapeutic Area : Nephrology
Highest Development Status : IND Enabling
Sponsor : Sofinnova Partners
Deal Size : $105.0 million
Deal Type : Series B Financing
Lead Product(s) : MTX652
Therapeutic Area : Nephrology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MTX652 is a potent and selective compound designed to improve mitochondrial quality and function by enhancing mitophagy through inhibition of USP30 enzyme. It is being evaluated for the treatment of acute kidney injury (AKI) following cardiac surgery.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 14, 2023
Lead Product(s) : MTX652
Therapeutic Area : Nephrology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MTX652
Therapeutic Area : Nephrology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mission has developed MTX652 to inhibit USP30 with the aim to enable appropriate degradation of dysfunctional mitochondria to preserve and improve cellular health. Mission is also investigating the potential of USP30 inhibitors to treat these diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : MTX652
Therapeutic Area : Nephrology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Contact Us!
Reset All
